来自美国国立卫生研究院心肺血液研究所的报告提示“心肌梗死（heart attack）患者于发病后2～3周接受自体骨髓干细胞治疗（therapy with bone-marrow derived cells），虽然安全，但在干细胞输注后六个月时未明显的效果，如心功能得到改善等。因此，关于利用骨髓干细胞治疗心肌梗死的疗效有待于进一步论证。

Delayed stem cell therapy following heart attack is safe but not effective

NIH-funded trial shows that therapy with bone-marrow derived cells does not improve heart function after six months; future clinical benefits still possible

Stem cells obtained from bone marrow, known as BMCs, can be safely injected into people 2-3 weeks following a heart attack, reports a new clinical trial supported by the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. However, while safe, the BMCs did not improve heart function six months after their administration.

This study, called LateTIME (Transplantation In Myocardial Infarction Evaluation), is the first trial to rigorously examine the safety and potential benefits of extending the timing of stem cell delivery to 2-3 weeks following a heart attack. The results will be presented Monday, Nov. 14, at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They will also appear online in the Journal of the American Medical Association.更多资讯，请参阅：http://www.nih.gov/news/health/nov2011/nhlbi-14.htm）